Virios Therapeutics, Inc. (VIRI)

Market Cap	8.19M
Revenue (ttm)	n/a
Net Income (ttm)	-5.30M
Shares Out	19.26M
EPS (ttm)	-0.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	197,373
Open	0.419
Previous Close	0.431
Day's Range	0.419 - 0.475
52-Week Range	0.279 - 2.420
Beta	1.88
Analysts	n/a
Price Target	n/a
Earnings Date	May 9, 2024

About VIRI

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly kn...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 17, 2020
• Employees: 4
• Stock Exchange: NASDAQ
• Ticker Symbol: VIRI